You're viewing our updated article page. If you need more time to adjust, you can return to the old layout.

CORRECTION article

Front. Pharmacol., 05 September 2022

Sec. Translational Pharmacology

Volume 13 - 2022 | https://doi.org/10.3389/fphar.2022.1014363

Corrigendum: Triglyceride-mimetic prodrugs of buprenorphine enhance oral bioavailability via promotion of lymphatic transport

  • 1. Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia

  • 2. Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia

Article metrics

View details

2

Citations

1,3k

Views

649

Downloads

In the published article, an author name was incorrectly written as Trevaksis. The correct spelling is Trevaskis.

Note this error is repeated in the main heading and in the citation information on page 1. It is also incorrect in the Copyright statement.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

lymphatic transport, prodrug, triglyceride mimetic, buprenorphine, first-pass metabolism, oral bioavailability, opioid analgesics

Citation

Quach T, Hu L, Han S, Lim SF, Senyschyn D, Yadav P, Trevaskis NL, Simpson JS and Porter CJH (2022) Corrigendum: Triglyceride-mimetic prodrugs of buprenorphine enhance oral bioavailability via promotion of lymphatic transport. Front. Pharmacol. 13:1014363. doi: 10.3389/fphar.2022.1014363

Received

08 August 2022

Accepted

09 August 2022

Published

05 September 2022

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

13 - 2022

Updates

Copyright

*Correspondence: Sifei Han, ; Christopher J. H. Porter,

†Present address: Tim Quach and Jamie S. Simpson, PureTech Health, Boston, MA, United States

‡These authors have contributed equally to this work

This article was submitted to Translational Pharmacology, a section of the journal Frontiers in Pharmacology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics